Molecular targets for epigenetic therapy of cancer

Rita Humeniuk, Prasun J. Mishra, Joseph R. Bertino, Debabrata Banerjee

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Recent advances in cancer research showed that changes of the cell "epigenome" contribute significantly to the development and progression of cancer. Similar to genetic alterations, epigenetic modifications can be transmitted to the next generation and used to turn off and/or on certain genes or pathways that may confer survival benefit to a malignant cell. However, epigenetic changes are readily reversible raising the possibility of "epigenetic therapy". A potential problem in this therapeutic approach is the lack of specificity, as epigenetic modifications are used by both normal and cancer cells to regulate expression of various genes. Ongoing studies to identify genes that are differentially expressed in cancer cells vs. normal cells are providing valuable information about molecular targets for epigenetic therapy. The present article will focus on summarizing some of these studies and will discus the differences between conventional chemotherapy and epigenetic therapy utilizing epigenetic drugs like DNA methyltransferase inhibitors or histone deacetylase inhibitors. Current perspectives on the future of epigenetic therapy are also discussed.

Original languageEnglish (US)
Pages (from-to)161-165
Number of pages5
JournalCurrent Pharmaceutical Biotechnology
Issue number2
StatePublished - 2009

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Pharmaceutical Science


  • Chromatin modifications
  • Combination chemotherapy
  • DNA methylation
  • Drug resistance
  • Epigenetic therapy


Dive into the research topics of 'Molecular targets for epigenetic therapy of cancer'. Together they form a unique fingerprint.

Cite this